Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04885569
Other study ID # PILL-CAMIAB-001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2023
Est. completion date June 2025

Study information

Verified date March 2024
Source Pakistan Institute of Living and Learning
Contact Imran Bashir Chaudhry, Prof.
Phone 02135871845
Email imran.chaudhry@pill.org.pk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study has both quantitative and qualitative components. The aim of study is to: 1. Culturally adapt and integrate the existing Motivational Interviewing with Cognitive Behavioral Therapy(MICBT) and Mindfulness based Relapse Prevention (MBRP) for people with Substance Use Disorder (SUD) in Pakistan 2. Test the feasibility and acceptability of the integrated intervention called CAMIAB ('CAMIAB' means success in Urdu) in a randomized control trial (RCT).


Description:

This study aims to culturally adapt the existing Motivational Interviewing with CBT (MICBT) and integrate this with Mindfulness-Based Relapse Prevention (MBRP) intervention for people with SUD and to test the feasibility, and acceptability of the intervention in a randomized control trial (RCT). First phase will be cultural adaptation of intervention through focus groups and individual interviews with key stakeholders . Phase two will be to test integrated MICBT and MBRP on a small group of participants N=12. Third phase will be a feasibility factorial randomized control trial with 260 participants with SUD (n=65). Participants will be recruited from primary care hospitals and drug rehabilitation centers in Karachi, Lahore, Rawalpindi, Hyderabad, and Peshawar Pakistan. Intervention will take place weekly over a period of 12 weeks. The intervention will consist of individual as well as group sessions. Assessments will be completed at baseline, after completion of intervention (12th week) and 24th week post randomization. All assessments will be administered by masked research assistants (RAs), not involved in delivering intervention sessions. The therapists delivering the intervention will be trained and will be provided ongoing supervisions by a senior therapist.


Recruitment information / eligibility

Status Recruiting
Enrollment 260
Est. completion date June 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria - Participants with substance use disorder - Meeting DSM-V criteria for substance use disorder - Age 18 years and above - Being able to understand spoken or written Urdu - Have undergone through the process of detoxification before study intervention Exclusion Criteria • Any evidence of organic brain disease, clinically significant cooccurring medical illness or mental illness to the extent that can impede their ability to provide informed consent or engagement in the intervention.

Study Design


Intervention

Behavioral:
Motivational interviewing with CBT (MICBT)
The culturally adapted MICBT will include approaches of motivational interviewing and offer ways of managing difficulties from a cognitive behavioural formulation.
Mindfulness based Relapse Prevention (MBRP)
MBRP will incorporate cognitive-behavioural skills (i.e., effective coping skills, self-efficacy, and recognizing common antecedents of relapse) with mindfulness-based practices to decrease the probability of relapse by increasing awareness and flexible responding in the presence of substance use triggers.
CAMIAB
This will be integrated CBT based motivational interviewing plus mindfulness based relapse prevention intervention group.

Locations

Country Name City State
Pakistan Pakistan Recovery Oasis Lahore

Sponsors (1)

Lead Sponsor Collaborator
Pakistan Institute of Living and Learning

Country where clinical trial is conducted

Pakistan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility measures Feasibility will be determined by recruitment rates, adherence rate and retention rates. The criterion for success of feasibility is to recruit >50% of eligible participants, adherence rate (number of home assignments completed; > 50%) and retention rate of 70%. From baseline to 3rd month (at the end of intervention)
Primary Acceptability measure Acceptability will be determined based on the number of sessions attended by participants and success criterion for intervention acceptability is mean attendance rate of at least 8 sessions. From baseline to 3rd month (at the end of intervention)
Secondary The Maudsley Addiction Profile The Maudsley Addiction Profile is a brief, questionnaire that measures problems in four domains: substance use, health risk behaviour, physical and psychological health, and personal/social functions. Change in problem scores from Baseline to 3rd Month and 6th month
Secondary The Short Warwick-Edinburgh Mental Well-being Scale The Short Warwick-Edinburgh Mental Well-being Scale is a 7 items measure that will be used to measure mental wellbeing. It consists of 7 statements on a 5 point Likert scale. The minimum scale score is 7 and the maximum is 35. The high score indicates high mental wellbeing. Change in scores from baseline to 3rd Month and 6th month
Secondary EuroQol-5 Quality of life will be measured using EuroQoL (EQ-5D) scale. This is a standardized instrument to measure health status and associated population utility weights. It measures five dimensions of health (mobility, self-care, usual activities, pain/ discomfort and anxiety/ depression) at different levels that include "no problems, slight problems, moderate problems, severe problems, and unable to do/extreme". Change in scores from baseline to 3rd Month and 6th month
Secondary Client service receipt inventory CSRI will be used to estimate the health and social services received. Changes from baseline to 3rd Month and 6th month
See also
  Status Clinical Trial Phase
Completed NCT02911285 - NAC for Treating Comorbid PTSD and SUD Phase 2
Recruiting NCT05632185 - Equine-assisted Therapy Effectiveness in Improving Emotion Regulation of Patients Suffering From Substance Use Disorder N/A
Completed NCT01270555 - Efficacy Of Bupropion For Attention Deficit Hyperactivity Disorder (ADHD) In Adults N/A
Active, not recruiting NCT03220373 - Predicting Dropout and Outcome From Neuropsychological Functions in SUD Patients
Completed NCT02132481 - Using Smartphones to Provide Recovery Support Services N/A